Idiopathic recurrent pericarditis refractory to colchicine treatment can reveal tumor necrosis factor receptor-associated periodic syndrome by L. Cantarini et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY Vol. 22, no. 4,1051-1058 (2009)
IDIOPATHIC RECURRENT PERICARDITIS REFRACTORY TO COLCHICINE
TREATMENT CAN REVEAL TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED
PERIODIC SYNDROME
L. CANTARINI, a.M. LUCHERINP, R. CIMAZ2, C.T. BALDARP, F. BELLISAI,
S. ROSSI PACCANP, F. LAGHI PASINP, P.L. CAPECCHP, G.D. SEBASTIANI4 and M. GALEAZZI
Interdepartmental Research Center ofSystemic Autoimmune andAutoinflammatory Diseases, Unit of
Rheumatology, Policlinico Le Scotte, University ofSiena, Siena; 'Department ofEvolutionary Biology,
University ofSiena, Siena; 2Department ofPaediatrics, Rheumatology Unit, Anna Meyer Children s
Hospital and University ofFlorence; 3Interdepartmental Research Center ofSystemic Autoimmune
andAutoinflammatory Diseases, Unit ofImmunological Sciences, Policlinico Le Seotte, University of
Siena, Siena; 4UOC ofRheumatology, S. Camillo-Forlanini Hospital, Rome, Italy
Received May 8, 2009 - AcceptedAugust 25, 2009
The first two authors contributed equally to this study
Recurrences develop in up to 20-50% of patients with acute pericarditis. Although different causes of
recurrent pericarditis have been identified, the etiology remains obscure in most cases which are therefore
labelled as idiopathic. Autoinflammatory syndromes include familial Mediterranean fever (FMF), due to
mutations in the MEFV gene, and tumor necrosis factor receptor-associated periodic syndrome (TRAPS),
due to mutations in the TNFRSFIA gene. Recurrent pericarditis is a common feature of both conditions,
but it rarely occurs alone. Colchicine is the standard treatment for FMF, while patients with TRAPS do
not respond to colchicine therapy, but are responsive to corticosteroids. Based on the proven efficacy of
colchicine in preventing polyserositis in FMF, colchicine has been proposed for the treatment of recurrent
pericarditis and is able to decrease the recurrence rate. Our aim was to investigate the possible involvement
of TNFRSFIA mutations in a group of patients with idiopathic recurrent pericarditis who were refractory to
colchicine treatment. Thirty consecutive patients (17 males, 13 females) diagnosed with idiopathic recurrent
pericarditis, who were characterized by a poor response to colchicine treatment, were enrolled in the study.
Mutations of the TNFRSFIA gene were searched for by amplifying,using polymerase chain reaction (PCR),
genomic DNA, and direct sequencing. TNFRSFIA mutations were found in 4 of the 30 patients. None of
these 4 patients had a family history of recurrent inflammatory syndromes or history of pericarditis. One
of the 4 patients had a novel heterozygous deletion (~YI03-RI04) and three patients carried a heterozygous
low-penetrance R92Q mutation. Our data suggest that TRAPS should be kept in mind in the differential
diagnosis of recurrent pericarditis, and mutation analysis of the TNFRSFIA gene should be considered, in
addition to MEFV analysis, in patients of Mediterranean origin. A poor response to colchicine treatment
and/or a steroid-dependence may be the clue to investigate TNFRSFIA mutations in patients with idiopathic
recurrent pericarditis.
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Recurrences develop in 20-50% of patients with
acute pericarditis (l). Clinical signs and symptoms
of acute pericarditis are characteristic of pericardial
disease and include elevation of inflammatory mark-
ers, precordial pain, fever, pericardial friction rub,
dyspnoea, and electrocardiogram changes. Clinical
manifestations during recurrences are similar to the
first episode, but the subsequent episodes are typical-
ly milder and may be limited to precordial pain only.
The number ofrecurrences and the intervals between
attacks can vary among patients. Recurrent pericar-
ditis may be isolated or associated with autoimmune
rheumatic diseases, viral or bacterial infections, and
neoplastic diseases (2). Although many causes have
been identified, the etiology of recurrent pericarditis
remains obscure in most cases (2).
Recurrent pericarditis, in the form of recurrent
polyserositis, is common in familial Mediterranean
fever (FMF) (3) and other auto-inflammatory
disorders, a group of diseases caused by primary
dysfunction of the innate immune system and
characterized by seemingly unprovoked attacks of
fever in association with localised inflammation that
can affect multiple organ systems (4).
Tumor necrosis factor receptor-l-associated
periodic syndrome (TRAPS) is the most common
auto-inflammatory autosomal dominant disorder.
TRAPS is caused by mutations in the gene
TNFRSFIA, located on chromosome 12p13,
encoding the 55-kD receptor for tumor necrosis
factor-a (TNF-a) (5). The disease is characterized
by recurrent attacks of fever typically lasting from
I to 3 weeks; in addition to fever, common clinical
features include mainly periorbital oedema, a
migratory erythematous plaque simulating erysipe1a
with underlying myalgia, and arthritis or arthralgia;
serous membrane inflammation is also possible (6-
7). Patients with TRAPS, unlike those with FMF,
respond poorly to colchicine treatment, but are
responsive to corticosteroids (8).
Although few patients with isolated serosal
pericardial involvement carrying mutations in
TNFRSFIA have been described (6), to the best
of our knowledge no studies have been published
on TNFRSF1A gene mutations in patients with
idiopathic recurrent pericarditis. Our aim is to
investigate the possible involvement of TNFRSFIA
gene mutations in a group ofpatients with idiopathic
recurrent pericarditis, who were refractory to
colchicine treatment.
MATERIALS AND METHODS
Patients
We enrolled 30 consecutive patients (17 males, 13
females) diagnosed with idiopathic recurrent pericarditis
who were characterized by a poor response to colchicine
treatment at standard dose (1-2 mg/day). All patients
were seen between September 2005 and November 2008
in our Institution, and were part of a larger cohort of
patients treated for idiopathic recurrent pericarditis. Table
I summarizes the main characteristics of the cohort of
patients enrolled in our study.
Each patient underwent detailed examinations in
order to rule out underlying diseases such as infections,
connective tissue disorders and malignancies. None of
the patients' past medical history was relevant for cardiac
surgery or radiation therapy. Criteria for the diagnosis of
recurrent pericarditis were: a) a documented first attack of
acute pericarditis according to accepted diagnostic criteria
(fever, pericardial friction rub, electrocardiographic
changes, echocardiographic evidence of pericardial
effusion, increases in the white blood cell count and/or
erythrocyte sedimentation rate (ESR) and/or C-reactive
protein (CRP) and/or serum amyloid A (SAA); and b)
evidence of at least one recurrence.
Recurrence was documented by pain and one or
more of the following signs: fever, pericardial friction
rub, electrocardiographic changes, echocardiographic
evidence of pericardial effusion, and elevations in
the white blood cell count or ESR or CRP or SAA.
Resistance to colchicine was defined as an unfavorable
clinical response with persistence or recurrence of
fever and pericardia! effusion appearance or worsening
during treatment. All patients were Caucasians of Italian
ancestry; they all provided written consent for genetic
testing, in accordance with the Helsinki Declaration and
local Ethical Committee regulations.
DNA extraction
Mononuclear cells were purified from peripheral
blood from healthy donors and patients (with informed
consent) by density gradient centrifugation on Ficoll-
Paque (Amersham Biosciences, Buckinghamshire, UK),
using a Beckman GS-6R tabletop centrifuge (Beckman
Coulter SpA, Milan, Italy). Cells were washed 2 X in
phosphate buffered saline (PBS), resuspended in RPMI
1640 (Invitrogen Ltd, Paisley, UK) (buffered with sodium
bicarbonate to pH 7.2) supplemented with 7.5% fetal calf
serum (FCS) (Hyclone, Thermofischer Scientific Inc,
SouthLogan, UT), plated in plastic flasks (Sarstedt AG,
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Fig. 1. A) DNA sequence electropherograms demonstrating the R92Q mutation in TNFRSFIA . WI; wild type. Sequence
electropherograms of TNFRSFIA exon 4 PCR amplification products from healthy donor and patient. The arrow
indicates the heterozygous G/A substitution resulting in the exchange ofarginine for glutamine at position 92. B) DNA
sequence electropherograms demonstrating the E148Q mutation in MEFV. WI; wild type. Sequence electropherograms
ofMEFV exon 2 PCR amplification products from healthy donor and patient. The arrow indicates the heterozygous G/C
substitution resulting in the exchange of glutamic acidfor glutamine at position 148.
Numbrecht, Germany) and incubated overnight at 37°C
in a humidified atmosphere with 5% CO2, Non-adherent
cells , which consisted principally of peripheral blood
lymphocytes (PBL), were centrifuged and resuspended in
fresh RPMI 1640 supplemented with 7.5% FCS. Genomic
DNA was isolated from peripheral blood lymphocytes of
patients and healthy controls using QIAamp DNA mini
Kit (Qiagen, Hilden Germany).
Genomic DNA amplification and mutation detection
The TNFRSF1A gene exons 2, 3, 4 and 6, which
encode for the extracellular domain of the 55-kD receptor
for TNF-a and the MEFV gene exons 2, 3, and 10, where
the majority oflmown mutations are found, were amplified
by polymerase chain reaction (PCR) using Expand High
Fidelity PCR System (Roche, Germany). PCR products
were purified using Wizard SV Gel and PCR Clean-Up
System (Promega, Madison, WI, USA). Sequencing was
carried out on the ABI 3730 DNA analyzer (Bio-Fab
Research srI, Italy) using the same primers as those used
in the PCR.
Restriction analysis ofthe Y103-R104 deletion
PCR of TNFRSF1A (exon 4) was performed in healthy
donor and patient. The 332 basepair amplicons were
then digested by RsaI restriction enzyme (Fermentas)
according to the manufacturer 's instructions.
RESULTS
Out of 30 patients tested, four carried a mutation
in the TNFRSFJA gene. Three of these (patients 12,
17 and 26 in Table I) carried a heterozygous low-
penetrance R92Q mutation (Fig. lA), and one (patient
4 in Table I) carried a novel heterozygous deletion
(~Y103-R104) (Fig. 2). The presence of the Y103-
RI04 deletion was further confirmed by restriction
analysis carried out with RsaI restriction enzyme; in
fact, deletion destroys an RsaI restriction site (GT~
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Fig. 2. Identification ofnovel mutation in exon 4 ofthe TNFRSF1A gene. DNA Sequence electropherograms ofTNFRSF1A
exon 4 PCR amplification product in forward (left) and reverse (right) from healthy donor (top) and patient (bottom).
The patient presents six nucleotide heterozygous deletion (TACCGG nucleotide sequence) resulting in an electroferogram
shift. This deletion causes the loss of tyrosine and arginine aminoacid at position 103 and 104, respectively (liY103-
RI04).
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Fig. 3. Restriction analysis ofthe Y103-R104 deletion by
RsaI restriction enzyme. PCR amplification TNFRSFIA
exon 4 was performed in healthy donor (I) and patient
(II). PCR product digestion by RsaI restriction enzyme
resulted in two bands of145 and 187 base pairs and three
bands of 145. 187 and 332 base pairs in healthy donor
(III) and patient (iV) , respectively.
AC) (Fig. 3). All four patients were diagnosed with
TRAPS. The mother, father and brother of patient 4
were clinically healthy and did not cany the mutation,
indicating that the mutation is likely to have occurred de
novo. The father of patient 12, the father of patient 17
and the mother of patient 26 also carried the mutation
R92Q, but they were all clinically healthy. Patient 12
also carried a low-penetrance mutation E148Q in the
MEFV gene (Fig. lB), not carried by the parents, but
was clinically diagnosed with TRAPS based on poor
response to colchicine, the duration of fever attacks (>
2 weeks), and late onset ofsymptoms (34 years).
These four patients, who, like all the others in
the study, had a poor response to colchicine, were
selected for treatment with the tumor necrosis factor
(TNF)-a neutralizing agent, etanercept (25 mg twice
weekly). Three additional patients who did not carry
mutations had increased (> '100 mg/L) levels of
circulating SAA, measured at least three times also
during symptom free intervals. Two ofthem (patients
9 and 13 in Table I) were successfully treated with
anakinra (100 mg/daily), a recombinant human
interleukin-l receptor antagonist, while the third
patient's parents refused this off-label treatment. In
the remaining cases indomethacin (50-150.mg/daily)
was added to colchicine. In a few patients (patients
11, 16, 19 and 21 in Table I) a further addition of
low-dose prednisone was required in order to prevent
recurrences. Eventually, all patients achieved good
disease control. At the time of genetic testing all
patients were taking colchicine 1-2 mg/daily,
Int. J. ImmunopathoI. PharmacoI.
Table I. Demographic, genetic and laboratory characteristics ofpatients.
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Pt Age at testing!Age at onset Sex SAA Mutations in Mutations in(yrs) (mgIL) TNFRSFIA MEFV
1 14/12 F 158 - -
2 28/27 F 58 - -
3 37/35 M 28 - -
4 28/13 M 181 Delta YI03-RI04 heterozygous -
5 26/22 M 42 - -
6 42/35 F 6 - -
7 22/17 M 8 - -
8 34/31 M 42 - -
9 27/24 F 146 - -
10 39/36 F 44 - -
11 59/51 F 88 - -
12 50/34 M 138 R92Q heterozygous E148Q homozygous
13 56/49 M 128 - -
14 32/29 F 16 - -
15 29/24 M 34 - -
16 48/43 M 68 - -
17 32/28 F 112 R92Q heterozygous -
18 16/13 M 26 - -
19 36/35 F 98 - -
20 24/21 M 48 - -
21 36/32 M 67 - -
22 41/37 F 59 - -
23 50/54 M 76 - -
24 23/22 M 8 - -
25 15/13 M 2 - -
26 41/38 F 121 R92Q heterozygous -
27 53/50 F 9 - -
28 29/28 M 39 - -
29 34/32 M 24 - -
30 17/16 F 26 - -
The table summarizes data from the entire cohort ofpatients enrolled. Gender, age at disease onset, age at the time of
genetic testing and the circulating levels ofserum amyloid A are shown. The results ofgenetic testing for mutations of
the gene responsible for the tumor necrosis factor-a receptor-associated periodic syndrome (TNFRSFlA gene) and of
the familial Mediterranean fever (MEFV gene) are also listed. List ofabbreviations: Pt = patient; yrs = years; SAA =
Serum AmyloidA; F = female; M = male
After one year offollow-up the four patients with
TRAPS who were treated with etanercept did not
show signs of disease relapse, and in all four, SAA
levels had already decreased to normal values a few
weeks after the initiation of treatment. The same was
true for the 2 patients treated with anakinra.
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DISCUSSION
Recurrences develop in 20-50% of adult patients
with acute pericarditis (1). The aetiology of acute
pericarditis and the cause of the recurrences remain
obscure in most cases, which are thus labeled as
idiopathic. Autoimmune responses may play a role
in the pathogenesis of recurrent pericarditis (9).
Other mechanisms that have been hypothesized
in the pathogenesis include insufficient treatment
during the first episode, possible re-infections
and augmented viral DNA/RNA replication in
pericardial tissue as possible consequences of long-
term treatment with steroids (10).
Recurrent pericarditis and other recurrent serositis,
often in the form of polyserositis, are common in
FMF and TRAPS (3, 6-7); furthermore, patients with
isolated recurrent pericarditis have been reported
both in FMF (11) and in TRAPS (6). Dode et al.
recently described two patients presenting recurrent
pericarditis as the sole clinical manifestation of
TRAPS and carrying the low-penetrance mutations
R92Q and P46L. In FMF, the incidence ofpericardial
involvement has been reported in 1.4% of cases
in a series (12), but the incidence rises to 27% in
echocardiographic studies (3).
Recently, Brucato et al. investigated the presence
ofFMF in two series ofItalian patients with recurrent
pericarditis; mutations in MEFV were searched
for respectively in 23 and 61 patients, but never
found (1, 13). In neither trial was genetic testing
for mutations in the TNFRSFlA gene carried out. In
our study we found a high incidence of TNFRSFIA
mutations, in comparison to the absence of MEFV
mutations, which may be due to the inclusion criteria
and demographic characteristics of patients: 1) the
enrolment of patients unresponsive to colchicine,
which ruled out the majority of FMF patients that
are typically responsive to colchicine (14); 2) the age
of disease onset in most cases in our series was> 20
years, a highly unlikely occurrence in FMF.
TNFRSF 1A is a transmembrane glycoprotein
consisting ofan extracellular region characterized by
a distinct pattern of 4 cysteine-rich domains (CRDs
1-4), a transmembrane region, and an intracellular
death domain (DD), which promotes TNFRSFIA
signaling (15) The binding site for TNFa is formed
by CRD2 and CRD3 (16) while CRD1 is the pre-
ligand assembly binding domain and is thought
to mediate TNFRSF 1A self-assembly (17). More
than 40 individual mutations have been identified,
the majority of which is localised in the CRD1
and CRD2 domains. Most mutations described
involve cysteine residues and are associated with a
higher disease penetrance; however several variants
involving other residues have been reported (18). In
vitro studies suggest that these TRAPS-associated
TNFRSFIA mutations are responsible for altered
TNFRSFIA expression, impaired TNF-a binding
and shedding (5), defective trafficking (19-20) and
abnormal apoptosis (21-22).
Three of our patients carried the R92Q mutation
in the TNFRSF1A gene and patient 4 carried a novel
deletion (~Y103-R104) in the CRD3 domain of
TNFRSFIA that might be involved in receptor
shedding, thus affecting TNFRSF 1A membrane
localization, or other receptor functions. The
actual functional implication of this deletion is
under investigation. The R92Q mutation is
a low-penetrance allele common in patients of
Mediterranean origin and has been found in 1.8%
of Caucasian patients with recurrent inflammatory
syndromes. R92Q mutation may cause a milder
disease and may often be associated with an
oligosymptomatic course (7, 23). The clinical
phenotype of TRAPS is expanding, and since the
discovery of TNFRSFIA, several studies have
indicated that the low-penetrance TNFRSFIA
variants might contribute to atypical inflammatory
responses in TRAPS, including cardiac diseases
(myocarditis and pericarditis) (6, 24), as in three of
our cases.
Based on the proven efficacy of colchicine in
preventing polyserositis in FMF, colchicine has been
proposed for the treatment of recurrent pericarditis
and is able to decrease the recurrence rate (25).
However, patients with TRAPS are characterized
by a poor response to colchicine and are typically
responsive to corticosteroid administration (8),
although steroids do not seem to protect completely
from the risk of amyloidosis which occurs in up to
25% of patients (26). Although TNF-a levels are not
usually significantly elevated in TRAPS patients
compared with healthy controls, etanercept has
been shown to elicit a beneficial response in patients
with TRAPS-related amyloidosis (27); it can reduce
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corticosteroid requirement and also prevent flare-ups
(28). Accordingly, our patients were successfully
treated with etanercept.
The patients who did not carry mutations, but
persistently showed elevated circulating SAA levels,
were considered to be affected by an unrecognized
autoinflammatory disorder, since a large percentage
ofthese patients demonstrated an elevated acute phase
response between clinically symptomatic attacks (7).
The choice of anakinra in our 2 patients proved
successful, in accordance with recent published data
(29), and was based on the demonstrated efficacy
of anakinra in the treatment of a large spectrum of
autoinflammatory diseases (30-31).
In conclusion, our preliminary data suggest that
TRAPS should be kept in mind in the differential
diagnosis of recurrent pericarditis, and mutation
analysis in TNFRSF1A should be considered,
in addition to MEFV analysis, in patients of
Mediterranean origin. A poor response to colchicine
treatment and/or a steroid-dependence may be the
clue to investigate TNFRSF1A mutations in patients
with idiopathic recurrent pericarditis. Furthermore,
the discovery of TNFRSF1A mutations may have
relevant clinical implications for patients, since
etanercept is still to be considered the first-line
therapy for TRAPS, although its long-term benefit
has yet to be fully elucidated.
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